Literature DB >> 17620943

Focal liver lesions: can SonoVue-enhanced ultrasound be used to differentiate malignant from benign lesions?

Ying Dai1, Min Hua Chen, Shan Shan Yin, Kun Yan, Zhi Hui Fan, Wei Wu, Yan Bin Wang, Wei Yang.   

Abstract

OBJECTIVE: To evaluate whether contrast-enhanced ultrasound (CEUS) with SonoVue could differentiate malignant focal liver lesions (FLLs) from benign lesions and provide lesion type diagnoses.
MATERIALS AND METHODS: Four hundred fifty-six patients with 554 FLLs were examined by CEUS with SonoVue using low mechanical index, nonlinear imaging techniques. Each lesion was characterized by 2 independent off-site readers as malignant or benign and given specific lesion type diagnosis, if possible, both at baseline ultrasound (US) and after SonoVue administration (CEUS). The final diagnosis was achieved by histopathology obtained from biopsy or surgical specimens, or by typical manifestation on contrast-enhanced CT or MRI.
RESULTS: The diagnostic accuracies of the 2 readers were 41.9% and 35.2% for baseline US, which improved significantly to 87.2% and 87.9% for CEUS (P < 0.05). Interreader agreement also increased with CEUS compared with baseline US (ê value changed from 0.49 to 0.77). The accuracy for lesion type diagnosis was 38.4% and 32.5% for baseline US, which increased to 77.6% and 78.0% for CEUS (P < 0.05).
CONCLUSIONS: CEUS with SonoVue improves differentiation between malignant and benign FLLs, and also provides improved lesion type (differential) diagnosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17620943     DOI: 10.1097/RLI.0b013e318050ab29

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  19 in total

1.  Contrast-enhanced ultrasound: The evolving applications.

Authors:  Hui-Xiong Xu
Journal:  World J Radiol       Date:  2009-12-31

2.  Malignant focal liver lesions at contrast-enhanced ultrasonography and magnetic resonance with hepatospecific contrast agent.

Authors:  M D'Onofrio; S Crosara; R De Robertis; S Canestrini; V Cantisani; G Morana; R Pozzi Mucelli
Journal:  Ultrasound       Date:  2013-12-13

3.  Acoustic attenuation by contrast agent microbubbles in superficial tissue markedly diminishes petechiae bioeffects in deep tissue.

Authors:  Ji Song; Alexander L Klibanov; John A Hossack; Richard J Price
Journal:  Invest Radiol       Date:  2008-05       Impact factor: 6.016

Review 4.  The current status of contrast-enhanced ultrasound in China.

Authors:  Hui-Xiong Xu; Ming-De Lu
Journal:  J Med Ultrason (2001)       Date:  2010-04-21       Impact factor: 1.314

5.  How often hepatocellular carcinoma has a typical pattern in contrast enhanced ultrasound?

Authors:  Alina Martie; Ioan Sporea; Roxana Sirli; Alina Popescu; Mirela Danila
Journal:  Maedica (Buchar)       Date:  2012-09

Review 6.  Contrast-enhanced US for characterization of focal liver lesions: a comprehensive meta-analysis.

Authors:  Menglin Wu; Liang Li; Jiahui Wang; Yanyan Zhang; Qi Guo; Xue Li; Xuening Zhang
Journal:  Eur Radiol       Date:  2017-11-30       Impact factor: 5.315

7.  Contrast Enhanced Ultrasound in CT-undetermined Focal Liver Lesions.

Authors:  S W Sandrose; S Karstrup; O Gerke; S Rafaelsen
Journal:  Ultrasound Int Open       Date:  2016-11

8.  Shear wave elastography-based ultrasomics: differentiating malignant from benign focal liver lesions.

Authors:  Wei Wang; Jian-Chao Zhang; Wen-Shuo Tian; Li-Da Chen; Qiao Zheng; Hang-Tong Hu; Shan-Shan Wu; Yu Guo; Xiao-Yan Xie; Ming-De Lu; Ming Kuang; Long-Zhong Liu; Si-Min Ruan
Journal:  Abdom Radiol (NY)       Date:  2020-06-20

9.  Magnetic resonance imaging of the liver: New imaging strategies for evaluating focal liver lesions.

Authors:  Kenneth Coenegrachts
Journal:  World J Radiol       Date:  2009-12-31

10.  Role of contrast-enhanced ultrasonography in percutaneous radiofrequency ablation of liver metastases and efficacy evaluation.

Authors:  Jie Wu; Wei Yang; Shanshan Yin; Jinyu Wu; Wei Wu; Kun Yan; Minhua Chen
Journal:  Chin J Cancer Res       Date:  2013-04       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.